JP2011500566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500566A5 JP2011500566A5 JP2010528889A JP2010528889A JP2011500566A5 JP 2011500566 A5 JP2011500566 A5 JP 2011500566A5 JP 2010528889 A JP2010528889 A JP 2010528889A JP 2010528889 A JP2010528889 A JP 2010528889A JP 2011500566 A5 JP2011500566 A5 JP 2011500566A5
- Authority
- JP
- Japan
- Prior art keywords
- lingo
- item
- seq
- amino acids
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 127
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 126
- 238000000034 method Methods 0.000 claims description 118
- 101150056950 Ntrk2 gene Proteins 0.000 claims description 77
- 239000000556 agonist Substances 0.000 claims description 61
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 239000005557 antagonist Substances 0.000 claims description 47
- 108091033319 polynucleotide Proteins 0.000 claims description 35
- 239000002157 polynucleotide Substances 0.000 claims description 35
- 102000040430 polynucleotide Human genes 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 210000002569 neuron Anatomy 0.000 claims description 14
- 239000004055 small Interfering RNA Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- 230000026731 phosphorylation Effects 0.000 claims description 5
- 238000006366 phosphorylation reaction Methods 0.000 claims description 5
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102000007562 Serum Albumin Human genes 0.000 claims description 3
- 108010071390 Serum Albumin Proteins 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 230000016273 neuron death Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- XMGNJVXBPZAETK-UHFFFAOYSA-N 2,5-dihydroxy-3-[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]-6-[7-(3-methylbut-2-enyl)-1h-indol-3-yl]cyclohexa-2,5-diene-1,4-dione Chemical compound C1=CC=C2C(C=3C(=O)C(O)=C(C(C=3O)=O)C=3C=4C=CC=C(C=4NC=3)CC=C(C)C)=C(C(C)(C)C=C)NC2=C1 XMGNJVXBPZAETK-UHFFFAOYSA-N 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 210000002768 hair cell Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 238000000338 in vitro Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 description 51
- 241000124008 Mammalia Species 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 7
- 241000125945 Protoparvovirus Species 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 229920001515 polyalkylene glycol Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 241000710929 Alphavirus Species 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000710778 Pestivirus Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000001044 sensory neuron Anatomy 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 101100027996 Mus musculus Omg gene Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 102000000343 Nogo Receptor 1 Human genes 0.000 description 2
- 108010041199 Nogo Receptor 1 Proteins 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 101100274557 Heterodera glycines CLE1 gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97933807P | 2007-10-11 | 2007-10-11 | |
| US60/979,338 | 2007-10-11 | ||
| PCT/US2008/011633 WO2009048605A1 (en) | 2007-10-11 | 2008-10-10 | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013180924A Division JP2013237704A (ja) | 2007-10-11 | 2013-09-02 | ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500566A JP2011500566A (ja) | 2011-01-06 |
| JP2011500566A5 true JP2011500566A5 (enExample) | 2011-11-24 |
| JP5674469B2 JP5674469B2 (ja) | 2015-02-25 |
Family
ID=40549476
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528889A Expired - Fee Related JP5674469B2 (ja) | 2007-10-11 | 2008-10-10 | ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法 |
| JP2013180924A Withdrawn JP2013237704A (ja) | 2007-10-11 | 2013-09-02 | ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013180924A Withdrawn JP2013237704A (ja) | 2007-10-11 | 2013-09-02 | ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20100297121A1 (enExample) |
| EP (1) | EP2205071B1 (enExample) |
| JP (2) | JP5674469B2 (enExample) |
| CN (1) | CN101980603A (enExample) |
| AU (1) | AU2008311251B9 (enExample) |
| CA (1) | CA2701189C (enExample) |
| WO (1) | WO2009048605A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7981420B2 (en) | 2000-12-22 | 2011-07-19 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. | Therapeutic use of antibodies directed against repulsive guidance molecule (RGM) |
| WO2004085648A2 (en) | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| BRPI0512500A (pt) | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | tratamento ou condições envolvendo desmielinação |
| RS53058B (sr) * | 2005-07-08 | 2014-04-30 | Biogen Idec Ma Inc. | Sp35 antitela i njihova primena |
| CN101277974A (zh) | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途 |
| JP2009517340A (ja) * | 2005-11-04 | 2009-04-30 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法 |
| NZ569428A (en) * | 2005-12-02 | 2012-11-30 | Biogen Idec Inc | Treatment of conditions involving demyelination with a Sp35 antagonist |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| US8128926B2 (en) * | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| SG181563A1 (en) | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| EP2523669B1 (en) | 2010-01-11 | 2016-12-07 | Inotek Pharmaceuticals Corporation | Combination, kit and method of reducing intraocular pressure |
| CA2792266A1 (en) | 2010-03-26 | 2011-09-29 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans using n6-cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
| CA2861009A1 (en) | 2012-01-26 | 2013-08-01 | Inotek Pharmaceuticals Corporation | Anhydrous polymorphs of [(2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof |
| ES2676725T3 (es) | 2012-01-27 | 2018-07-24 | AbbVie Deutschland GmbH & Co. KG | Composición y método para el diagnóstico y el tratamiento de enfermedades asociadas con la degeneración de las neuritas |
| EP2849787A4 (en) * | 2012-05-14 | 2016-06-15 | Biogen Ma Inc | LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING ENGINE NEURONS |
| EP2968389A4 (en) | 2013-03-15 | 2016-08-24 | Inotek Pharmaceuticals Corp | OPHTHALMIC FORMULATIONS |
| MX2017009038A (es) | 2015-01-08 | 2017-10-25 | Biogen Ma Inc | Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes. |
| EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| WO2017019905A1 (en) | 2015-07-28 | 2017-02-02 | Otonomy, Inc. | Treatment using truncated trk b and trk c antagonists |
| GB2547179A (en) * | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| MA45668A (fr) * | 2016-07-13 | 2019-05-22 | Biogen Ma Inc | Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
| EP3717514A1 (en) | 2017-11-30 | 2020-10-07 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
| CN108535076A (zh) * | 2018-03-19 | 2018-09-14 | 广州江元医疗科技有限公司 | 一种应用于免疫细胞化学p16蛋白染色的封闭液及其制备方法 |
| JP2023524686A (ja) * | 2020-04-29 | 2023-06-13 | エモリー ユニバーシティー | Ｔｒｋｂ活性化剤としてのｎ－アセチルセロトニン誘導体及びその使用 |
| EP4342908A4 (en) * | 2021-06-17 | 2024-10-23 | Fapon Biotech Inc. | CHIMERIC IMMUNGLOBULIN |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) * | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| GB8601597D0 (en) * | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5892019A (en) * | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5413923A (en) * | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5780225A (en) * | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5532351A (en) * | 1990-07-12 | 1996-07-02 | Arch Development Corporation | Nucleic acid sequences encoding OMGP |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69408541T2 (de) * | 1993-11-23 | 1998-08-06 | Genentech, Inc., South San Francisco, Calif. | Kinaserezeptoraktivierungstest |
| DE4415539C2 (de) * | 1994-05-03 | 1996-08-01 | Osama Dr Dr Med Omer | Pflanzen mit virustatischer und antiviraler Wirkung |
| US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| CA2202032C (en) * | 1994-10-25 | 2009-06-16 | Satoshi Ono | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| JP2978435B2 (ja) * | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| CN1202247C (zh) * | 1996-07-12 | 2005-05-18 | 基因技术股份有限公司 | 嵌合异源多亚基粘附素 |
| CZ399A3 (cs) * | 1996-07-19 | 1999-06-16 | Amgen Inc. | Polypeptidová analoga kationaktivních polypeptidů |
| WO1998011243A2 (en) * | 1996-09-11 | 1998-03-19 | The General Hospital Corporation | Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
| WO1998010785A1 (en) * | 1996-09-13 | 1998-03-19 | Advanced Medicine Research Institute | Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders |
| US6420140B1 (en) * | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| US6156728A (en) * | 1996-11-01 | 2000-12-05 | Genentech, Inc. | Treatment of inner ear hair cells |
| RO120148B1 (ro) * | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| DK1205546T3 (da) * | 1997-10-24 | 2006-04-03 | Genentech Inc | Polypeptider og nucleinsyrer kodende derfor |
| US7282482B2 (en) * | 1998-04-08 | 2007-10-16 | The Regents Of The University Of California | NGF for the prevention of demyelination in the nervous system |
| US7034132B2 (en) * | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| CA2373721C (en) * | 1999-07-02 | 2013-10-15 | Genentech, Inc. | Compounds that bind her2 |
| AU6181200A (en) * | 1999-07-29 | 2001-02-19 | Helix Research Institute | Stomach cancer-associated gene |
| US6680209B1 (en) * | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
| US20040252299A9 (en) * | 2000-01-07 | 2004-12-16 | Lemmo Anthony V. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
| US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| US6881719B2 (en) * | 2000-01-18 | 2005-04-19 | Mcgill University | β-turn peptidomimetic cyclic compounds |
| MXPA02010011A (es) * | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| WO2002000677A1 (en) * | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20030162734A1 (en) * | 2001-06-28 | 2003-08-28 | Miller Carol A. | Modulation of DENN-MADD expression and interactions for treating neurological disorders |
| US7223558B2 (en) * | 2001-07-11 | 2007-05-29 | Bristol-Myers Squibb Company | Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20050123990A1 (en) * | 2001-09-26 | 2005-06-09 | Incyte Corporation | Membrane associated proteins |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| CA2481074A1 (en) * | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| US6919426B2 (en) * | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| US7816497B2 (en) * | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| WO2004085648A2 (en) * | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| US7205387B2 (en) * | 2003-08-28 | 2007-04-17 | Agency For Science, Technology And Research | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist |
| JP4969440B2 (ja) * | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| BRPI0512500A (pt) * | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | tratamento ou condições envolvendo desmielinação |
| US20060009288A1 (en) * | 2004-07-07 | 2006-01-12 | Devos John A | Conveying information to an interrogator using resonant and parasitic radio frequency circuits |
| EP2329714A1 (en) * | 2004-08-03 | 2011-06-08 | Biogen Idec MA Inc. | Influence of TAJ in the neuronal functions |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AR054260A1 (es) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos |
| GT200600240A (es) * | 2005-06-06 | 2007-03-14 | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
| EP2581440B1 (en) * | 2005-06-08 | 2016-03-16 | The University of North Carolina At Chapel Hill | Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics |
| RS53058B (sr) * | 2005-07-08 | 2014-04-30 | Biogen Idec Ma Inc. | Sp35 antitela i njihova primena |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ569428A (en) * | 2005-12-02 | 2012-11-30 | Biogen Idec Inc | Treatment of conditions involving demyelination with a Sp35 antagonist |
| US20070186296A1 (en) * | 2006-02-02 | 2007-08-09 | Wyeth | Cloning, characterization, and application of tnfrsf19 in neurological disorders |
| JP2009525346A (ja) * | 2006-02-03 | 2009-07-09 | ワイス | Ｌｉｎｇｏ−１構造 |
| WO2007098283A2 (en) * | 2006-02-27 | 2007-08-30 | Biogen Idec Ma Inc. | Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders |
| EP2068866A4 (en) * | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| EP2084190B1 (en) * | 2006-11-17 | 2011-03-23 | Novartis AG | Lingo binding molecules and pharmaceutical use thereof |
| WO2008078179A1 (en) * | 2006-12-20 | 2008-07-03 | Rinat Neuroscience Corporation | Trkb agonists for treating autoimmune disorders |
| US8128926B2 (en) * | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| WO2009061500A1 (en) * | 2007-11-08 | 2009-05-14 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| EP2307042B1 (en) * | 2008-06-25 | 2014-03-26 | H. Lundbeck A/S | Modulation of the trpv : vps10p-domain receptor system for the treatment of pain |
| DK2982695T3 (da) * | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| CA2743473C (en) * | 2008-11-17 | 2022-06-14 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
| JP5289986B2 (ja) * | 2009-01-20 | 2013-09-11 | 株式会社オーディオテクニカ | 赤外線送信機 |
-
2008
- 2008-10-10 CA CA2701189A patent/CA2701189C/en active Active
- 2008-10-10 US US12/682,505 patent/US20100297121A1/en not_active Abandoned
- 2008-10-10 WO PCT/US2008/011633 patent/WO2009048605A1/en not_active Ceased
- 2008-10-10 JP JP2010528889A patent/JP5674469B2/ja not_active Expired - Fee Related
- 2008-10-10 CN CN2008801211784A patent/CN101980603A/zh not_active Withdrawn
- 2008-10-10 AU AU2008311251A patent/AU2008311251B9/en not_active Ceased
- 2008-10-10 EP EP08837617.3A patent/EP2205071B1/en active Active
-
2013
- 2013-09-02 JP JP2013180924A patent/JP2013237704A/ja not_active Withdrawn
-
2016
- 2016-05-16 US US15/155,399 patent/US20160354465A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500566A5 (enExample) | ||
| JP2009544703A5 (enExample) | ||
| JP5674469B2 (ja) | ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法 | |
| Kreider et al. | Enrichment of Schwann cell cultures from neonatal rat sciatic nerve by differential adhesion | |
| Takechi et al. | A melanosomal membrane protein is a cell surface target for melanoma therapy. | |
| NZ568705A (en) | Methods for promoting neurite outgrowth and survival of dopaminergic neurons | |
| JP2010518007A5 (enExample) | ||
| RS60762B1 (sr) | Oligonukleotidna jedinjenja za ciljane irnk hantingtina | |
| CN113151285B (zh) | 人4IgB7-H3的突变编码基因及其调节免疫的应用 | |
| JPH08500736A (ja) | 細胞接着のオリゴヌクレオチド調節 | |
| WO2022217923A1 (zh) | 一种抗igf-1r抗体及其应用 | |
| EP1814579B1 (fr) | Netrine 4 mutee, ses fragments et leur utilisation comme medicaments | |
| US20220105202A1 (en) | Universal multi-functional gsh-responsive silica nanoparticles for delivery of biomolecules into cells | |
| CN107541513A (zh) | 用于沉默cd317的小分子干扰rna、重组载体、药物及其应用 | |
| JP2009518299A5 (enExample) | ||
| CN1209068A (zh) | 作为基因治疗所用的dna载体的透明质酸及治疗异常视网膜血管化的vegf反义dna | |
| EP2001492B1 (en) | A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same | |
| JP2009538282A5 (enExample) | ||
| Nie et al. | DNA nanodevice as a multi-module co-delivery platform for combination cancer immunotherapy | |
| Liu et al. | Mesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases | |
| US12378280B2 (en) | Deoxynucleic guanidines (DNG)-modified oligonucleotides and methods of synthesizing deoxynucleic guanidine strands | |
| JP2009504689A (ja) | Ｇｄｎｆ由来ペプチド | |
| CN116036243A (zh) | 受体偏向的peg化il-2变体组合及其应用 | |
| CN114450302A (zh) | Mhc ii类分子及其使用方法 | |
| WO1992019252A1 (en) | Antisense oligonucleotides to c-kit proto-oncogene and uses thereof |